SUVPF:OTC-Sartorius Aktiengesellschaft (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 558.00

Change

0.00 (0.00)%

Market Cap

USD 37.26B

Volume

3.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
SEMHF Siemens Healthineers AG

N/A

USD57.50B 32.24 N/A
WXIBF WuXi Biologics (Cayman) Inc

+0.28 (+2.08%)

USD52.74B 217.58 24.91
YACAF Yancoal Australia Ltd

N/A

USD51.96B 0.20 N/A
HENOF Henkel AG & Co. KGaA

N/A

USD45.59B 29.48 15.78
MQBKY Macquarie Group Limited

+1.97 (+1.59%)

USD45.00B 25.70 9.51
PETFF PTT Public Company Limited

N/A

USD36.66B 32.14 0.21
SZHIF Shenzhou International Group H..

N/A

USD36.32B 42.19 N/A
SARTF Sartorius Aktiengesellschaft

+36.00 (+7.74%)

USD36.24B 100.87 59.28
HDALF Haidilao International Holding..

N/A

USD34.12B 722.22 8.49

ETFs Containing SUVPF

Symbol Name Weight Mer Price(Change) Market Cap
C007:F ComStage MDAX UCITS ETF 0.00 % 0.30 %

+0.39 (+1.34%)

USD0.19B
E907:F Lyxor 1 MDAX UCITS ETF 0.00 % 0.30 %

+2.18 (+1.28%)

USD0.11B
E908:F Lyxor 1 TecDAX UCITS ETF 0.00 % 0.40 %

+0.24 (+0.91%)

USD0.08B
EL4C:F Deka STOXX Europe Strong .. 0.00 % 0.67 %

+1.10 (+1.94%)

USD0.17B
EL4E:F Deka STOXX Europe Strong .. 0.00 % 0.65 %

+0.75 (+1.91%)

USD0.02B
ELF1:F Deka MDAX UCITS ETF 0.00 % 0.00 %

+4.25 (+1.39%)

USD0.44B
EXS2:F iShares TecDAX UCITS ETF .. 0.00 % 0.51 %

+0.37 (+1.20%)

USD5,933.97B
EXS3:F iShares MDAX UCITS ETF (D.. 0.00 % 0.51 %

+3.70 (+1.38%)

USD5,933.92B
C007:XETRA Lyxor MDAX (DR) UCITS ETF 0.00 % 0.30 %

+0.42 (+1.46%)

USD0.24B
E907:XETRA Lyxor 1 MDAX UCITS ETF 0.00 % 0.30 %

+2.82 (+1.66%)

USD0.21B
E908:XETRA Lyxor 1 TecDAX UCITS ETF 0.00 % 0.40 %

+0.33 (+1.23%)

USD0.10B
EL4C:XETRA Deka STOXX Europe Strong .. 0.00 % 0.67 %

+0.95 (+1.68%)

USD0.29B
ELF1:XETRA Deka MDAX UCITS ETF 0.00 % 0.00 %

+4.55 (+1.49%)

USD0.69B
EXS2:XETRA iShares TecDAX UCITS ETF .. 0.00 % 0.51 %

+0.41 (+1.32%)

USD5,933.97B
EXS3:XETRA iShares MDAX UCITS ETF (D.. 0.00 % 0.51 %

+3.90 (+1.45%)

USD5,933.92B

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.23% N/A N/A 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.23% N/A N/A 62% D-
Trailing 12 Months  
Capital Gain 88.58% N/A N/A 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.58% N/A N/A 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 48.39% N/A N/A 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.39% N/A N/A 73% C
Risk Return Profile  
Volatility (Standard Deviation) 54.74% N/A N/A 45% F
Risk Adjusted Return 88.41% N/A N/A 96% A
Market Capitalization 37.26B N/A N/A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 120.70 N/A N/A 7% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 72.84 N/A N/A 3% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 28.00% N/A N/A 94% A
Return on Invested Capital -13.90% N/A N/A 22% F
Return on Assets 9.79% N/A N/A 94% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.28 N/A N/A 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike